In vivo effects of Sarconeos (API BIO101) on a mouse model of severe spinal muscular atrophy

Cynthia Bézier1,2, Steve Cottin2, Pierre Dilda1, René Lafont1,3, Stanislas Veillet1, Frédéric Charbonnier2, Mathilde Latil1, Olivier Biondi2
1/ Biophytis, Sorbonne University – BC9, 4 place Jussieu, 75005 Paris, France; 2/ Paris Descartes University, Faculty of Fundamental and Biomedical Sciences, INSERM UMR-S 1124, Paris, 75005, France; 3/ Sorbonne University, Paris-Seine Biology Institute (BIOSPE), CNRS, 75005 Paris, France

Abstract Number: P36-309-#277

Introduction
Spinal Muscular Atrophy (SMA) is an autosomal recessive neurodegenerative disease characterized by the loss of spinal cord motor neurons and progressive muscular atrophy, due to insufficient level of Survival of Motor Neuron (SMN) protein (Crawford and Pardo, 1996; Lefebvre et al., 2005). SMA is now defined as a non-cell autonomous disease, involving numerous tissues and cell-types, including skeletal muscles (Tony Frugier et al., 2001).

Sarconeos is a first-in-class drug candidate based on the activation of the MAS receptor (major player of the renin-angiotensin system) which demonstrated meaningful activity in animal models of muscular dystrophies. Sarconeos is being tested in an ongoing Phase 2b (SARA-INTI) clinical trial in elderly patients with sarcopenia, an age-related degeneration of skeletal muscles, leading to loss of mobility. BIO101 is the active principal ingredient of Sarconeos.

In SMA-like mouse models, it has been shown that NMDA receptor activation and partial invalidation of IGF1-R result in lifespan and motor functions improvement, motor-neurons protection and SMN overexpression in the spinal cord by activating the AKT/ERK pathway and inhibiting the ERK/CREB pathway (Branchu et al., 2013; Biondi et al., 2015). In this context, using BIO101 administration could improve the neuromuscular functions in SMA by stimulating muscular anabolism and increasing SMN expression through the activation of the PI3K/AKT pathway via the MAS receptor.

Severe SMA-like mouse model
• Smn±/±, huSMN2/2 (Hsieh-Li et al. 2000)
• Mean survival of 12 days post-natal (P12)
• 50% loss of spinal motor neurons
• Severe muscle atrophy

In pathological conditions: Smn±/±, huSMN2/2

From birth (P0) to 11 days of age (P11): per os treatment with BIO101 (50mg/kg/day) or vehicle (VH; cyclodextrin)

Results

1. Systemic benefits

Figure 1: Effect of BIO101 chronic treatment on body weight and survival in SMA-like mice. (A) Weight curve of vehicle treated control mice and VH- or BIO101-treated SMA-like mice (n=16 in each group, *p<0.05, **p<0.01) and (B) survival analysis of SMA mice treated with BIO101 or vehicle (n=16 in each group, *p<0.05, **p<0.01). BIO101 induces a statistically significant limitation of weight loss from P9 and an increase in survival at P11 in SMA-like mice.

2. Tissue effects - In muscles: Plantaris

Figure 2: Effect of BIO101 chronic treatment on muscular phenotype in SMA-like mice. (A) Haematoxylin-eosin staining, (B) quantification of the cross-sectional area and (C) cross-sectional area variability analysis of myofibers in the Plantaris of vehicle treated control mice and VH- or BIO101-treated SMA-like mice at P11 (n=4 in each group, *p<0.05).

BIO101 limits the muscular atrophy, and restores the myofiber size variability in the fast-twitch extensor plantaris of SMA-like mice. Similar results are found also in the fast-twitch flexor Tibialis and the slow-twitch extensor Soleus.

- In lumbar motor neurons

Figure 3: Effect of BIO101 chronic treatment on lumbar motor neurons phenotype in SMA-like mice. (A) Immunofluorescence of ChAT-positive motor neurons in the lumbar spinal cord (L1–L5) (B) Quantitative analysis of the number of total, medial and lateral motor neurons per hemi-ventral horn (n=5 in each group, *p<0.05) (C) Distribution of motor neurons according to their soma surface in the lumbar spinal cord (n=5 in each group, *p<0.05) of control mice compared with SMA-like mice treated with vehicle or BIO101 at P11.

BIO101 efficiently limits lateral motor neurons loss in the lumbar spinal cord of SMA-like mice by protecting the large-area motor neurons.

3. Molecular effects

- In muscles: Plantaris

Figure 4: Effect of BIO101 on AKT, ERK pathways and on SMN expression in SMA-like mice. (A) Western blot analysis and quantification of (B) AKT phosphorylation, (C) ERK phosphorylation and (D) SMN expression in the Plantaris of vehicle-treated control mice and VH- or BIO101-treated SMA-like mice at P11 (n=2 in each group with ≥6 mice in each group)

BIO101 activates PI3K-AKT signaling pathway and inhibits ERK signaling pathway without having any effect on SMN expression in the Plantaris of SMA-like mice. Similar results are also found in the Tibialis and the Soleus.

- In lumbar motor neurons

Figure 5: Effect of BIO101 on AKT and ERK pathways and on SMN expression in SMA-like mice. (A) Western blot analysis and (B) quantification of AKT phosphorylation, (C) ERK phosphorylation and (D) SMN expression in the lumbar spinal cord of vehicle-treated control mice and VH- or BIO101-treated SMA-like mice at P11 (n=2 in each group for AKT and ERK pathways, n=4 in each group for SMN expression)

BIO101 induces an activation of PI3K-AKT signaling pathway and an inhibition of ERK signaling pathway without having any effect on SMN expression in the lumbar spinal cord of SMA-like mice.

Conclusions

BIO101 induces a statistically significant limitation of weight loss from P9 and an increase in survival at P11 in SMA-like mice.

BIO101 effects are SMN expression-independent BIO101, for which Orphan Disease Designation has been granted in Duchenne Muscular Dystrophy, could be considered as a key molecule for a new therapeutic strategy in combination with gene therapies for SMA patients.